Business Description
Traws Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US68232V3069
Description
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.33 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -39.74 | |||||
| Beneish M-Score | -2.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -18.1 | |||||
| 3-Year EBITDA Growth Rate | 23.4 | |||||
| 3-Year EPS without NRI Growth Rate | 25.3 | |||||
| 3-Year FCF Growth Rate | 24.5 | |||||
| 3-Year Book Growth Rate | 0.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 4.31 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.37 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.92 | |||||
| 9-Day RSI | 53.68 | |||||
| 14-Day RSI | 45.73 | |||||
| 6-1 Month Momentum % | -15.5 | |||||
| 12-1 Month Momentum % | -45.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.93 | |||||
| Quick Ratio | 1.93 | |||||
| Cash Ratio | 1.74 | |||||
| Days Sales Outstanding | 28.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -8572.12 | |||||
| Net Margin % | -8033.63 | |||||
| FCF Margin % | -7881.86 | |||||
| ROE % | -124.39 | |||||
| ROA % | -68.04 | |||||
| ROIC % | -1940.79 | |||||
| ROC (Joel Greenblatt) % | -93139.42 | |||||
| ROCE % | -111.06 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 36.1 | |||||
| PB Ratio | 1.49 | |||||
| Price-to-Tangible-Book | 1.49 | |||||
| EV-to-EBIT | 0.28 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | 0.28 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-Revenue | -24.38 | |||||
| EV-to-Forward-Revenue | 1.04 | |||||
| EV-to-FCF | 0.31 | |||||
| Price-to-Median-PS-Value | 1.49 | |||||
| Price-to-Net-Current-Asset-Value | 1.54 | |||||
| Price-to-Net-Cash | 2.15 | |||||
| Earnings Yield (Greenblatt) % | 357.14 | |||||
| FCF Yield % | -163.42 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers